AIM1 Ventures Inc. (“AIM1”) is pleased to announce that the previously announced subscription receipt private placement (the “Offering”) of James E. Wagner Cultivation Ltd. (“JWC”) has closed. Pursuant to the Offering, JWC issued 16,078,447 subscription receipts (“Subscription Receipts”) at a price of C$1.15 per Subscription Receipt (the “Issue Price”) for aggregate gross proceeds of C$18,490,214.05.

Haywood Securities Inc. (“Haywood”) and Eight Capital (“Eight”) acted as co-lead agents for the Offering, together with and on behalf of a syndicate of agents including AltaCorp Capital Inc., INFOR Financial Inc., Beacon Securities Limited and Mackie Research Capital Corporation (together with Haywood and Eight, the “Agents”). The Offering was conducted pursuant to the terms of an agency agreement (the “Agency Agreement”) dated April 27, 2018 among AIM1, JWC and the Agents.


The Subscription Receipts were issued pursuant to a subscription receipt agreement (the “Subscription Receipt Agreement”) among JWC, Haywood, Eight and TSX Trust Company, as subscription receipt agent. Pursuant to the Subscription Receipt Agreement, the gross proceeds of the Offering less the costs and expenses of the Agents (including legal fees, disbursements and applicable taxes) (the “Escrowed Subscription Funds”), have been placed in escrow pending satisfaction of certain escrow release conditions (the “Escrow Release Conditions”). Upon the satisfaction of the Escrow Release Conditions on or prior to August 25, 2018 (the “Escrow Release Deadline”), each Subscription Receipt shall be automatically converted by JWC, without the payment of additional consideration, into one common share in the capital of JWC (a “Subscription Share”) and one half of one common share purchase warrant of JWC (each whole warrant, a “Subscription Warrant”). Each whole Subscription Warrant shall entitle the holder thereof to purchase one common share in the capital of JWC (each, a “Warrant Share”) at any time for a period of 24 months following the date of the completion of the Transaction (as defined below), at an exercise price of $1.50 per Warrant Share, subject to adjustment as provided in the warrant indenture (the “Warrant Indenture”) dated April 27, 2018 entered into among AIM1, JWC and TSX Trust Company, as warrant agent.

The Subscription Receipts are being issued in connection with the previously-announced proposed going-public transaction (the “Transaction”) involving AIM1 and JWC, which constitutes the “qualifying transaction” of AIM1 pursuant to the policies of the TSX Venture Exchange (the “TSXV”).

Following completion of the Transaction, each Subscription Share will automatically be exchanged for one common share in the capital of AIM1 (post-Transaction) (the “Resulting Issuer”), and each Subscription Warrant will be exchanged for one common share purchase warrant in the capital of the Resulting Issuer, pursuant to the terms of the Warrant Indenture.

In consideration of the services provided by the Agents in connection with the Offering, the Agents received 762,149 compensation options (the “Compensation Options”). In addition, the Agents are entitled to receive a cash commission (the “Agents’ Commission”) equal to $876,473.36, to be paid out of the Escrowed Subscription Funds upon satisfaction of the Escrow Release Conditions prior to the Escrow Release Deadline. Provided the Escrow Release Conditions are satisfied, each Compensation Option will be exercisable to purchase one common share in the capital of JWC at the price of $1.15 per share and, following completion of the Transaction, assuming such Compensation Option was not previously exercised, each one Compensation Option will automatically be exchanged for one compensation option of the Resulting Issuer which shall be exercisable to purchase one common share in the capital of the Resulting Issuer (subject to any necessary adjustments, as applicable) at a price of $1.15 per share for a period of 24 months from the date the Escrow Release Conditions are satisfied, if satisfied prior to the Escrow Release Deadline.

All securities issued pursuant to the Offering are subject to a hold period ending on the later of: (a) August 28, 2018; or (b) the date that JWC becomes a reporting issuer pursuant to applicable securities laws.

About JWC

JWC is a premier cannabis business that focuses on growing its cannabis aeroponically, using cutting edge cannabis technologies and growing practices. Although many methods are used to produce cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), it is important to note that these methods will often result in a variety of different outcomes. Through its various proprietary technologies involved in all stages of the growing process, JWC prides itself on continuing to provide patients with clean, consistent medical cannabis products of high quality.

JWC has entered into a strategic partnership with Canopy Growth Corporation (“Canopy Growth”) and its strategic investment arm, Canopy Rivers Corporation. The strategic partnership provides JWC with access to high-quality genetics sourced from around the world, industrial scale cannabis oil infrastructure, and a rigorous Quality Assurance program. Through its strategic partnership, JWC is also a partner of CraftGrow, an online store that provides fast shipments of cannabis to customers. In addition, JWC has access to the Tweed Main Street online marketplace that provides JWC with direct exposure to Canopy Growth’s operational, distribution, marketing and sales infrastructure.

For more information about the Offering, please contact Nathan Woodworth, the President and Chief Executive Officer of JWC:

Nathan Woodworth
James E. Wagner Cultivation Ltd.
855 Trillium Drive, Unit 2
Kitchener, ON N2R 1J9
Email: Nathan@jwcmed.com
Phone: (519) 594-0144 x421

Trading Halt

Trading in the common shares of AIM1 was voluntarily halted on January 4, 2018 as a result of the announcement of the intention to complete the Transaction and will remain halted until the documentation required by the TSXV in connection with the Transaction has been reviewed and accepted by the TSXV. Subject to compliance with the policies of the TSXV, AIM1 may also request that trading in the common shares of AIM1 remain halted pending the closing or abandonment of the Transaction.

For more information, please contact Aaron Salz, the Chief Executive Officer and a director of AIM1.

Aaron Salz, CEO
info@stoicadvisory.com
416-565-4457

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

The TSXV has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

Disclaimer for Forward-Looking Information

This press release contains forward-looking statements and forward-looking information that are based on the beliefs of management and reflect AIM1’s current expectations. When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release include information relating to the release of the Escrowed Subscription Funds and the completion of the Transaction (including regulatory approval thereof). Such statements and information reflect the current view of AIM1. Risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following risks: there is no assurance that the Escrow Release Conditions will be satisfied and the Transaction completed. In particular, post-closing of the Transaction, the Resulting Issuer may require additional financing from time to time in order to continue its operations. Financing may not be available when the Resulting Issuer needs it; new laws or regulations could adversely affect the Resulting Issuer’s business and results of operations; the stock markets have experienced volatility that often has been unrelated to the performance of companies. These fluctuations may adversely affect the price of shares in the capital of the Resulting Issuer, regardless of its operating performance; there is no assurance that the TSXV will approve the Transaction.

There are a number of important factors that could cause the AIM1’s and the Resulting Issuer’s actual results to differ materially from those indicated or implied by forward-looking statements and information. Such factors include, among others: currency fluctuations; limited business history of AIM1; disruptions or changes in the credit or security markets; results of operation activities and development of projects; project cost overruns or unanticipated costs and expenses, fluctuations in the Resulting Issuer’s product prices, and general market and industry conditions.

AIM1 cautions that the foregoing list of material factors is not exhaustive. When relying on the AIM1’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. AIM1 has assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS PRESS RELEASE REPRESENTS THE EXPECTATIONS OF AIM1 AS OF THE DATE OF THIS PRESS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE AIM1 MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.

Source: globenewswire.com

  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less

Recap of special management call includes upcoming corporate milestones and details of proposed combination with established beverage manufacturer

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to provide a recorded recap of the special management call held on Tuesday November 24, 2020. The call discussed upcoming corporate milestones and reviewed recent developments at the developer and manufacturer of cannabinoid‐infused beverages and consumer products for in‐house brands and white label clients.

Keep reading... Show less

Strong Innovation Pipeline Continues to Drive Market Share Growth
Broken Coast’s First Foray into Cannabis 2.0
Solei Introduces First Limited Release Vape on the Market
Solei, RIFF, Good Supply and B!NGO Expand Product Offerings

Aphria Inc. (” Aphria ” or the ” Company “) ( TSX: APHA and NASDAQ: APHA ), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, today announced the expansion of its 510 Vape offering across its award-winning adult-use brand portfolio.

Keep reading... Show less

Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court before the December 1 2020 DEADLINE . A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=aurora-cannabis-inc&id=2437 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf Solutions“, “OILS”, or the “Company”), Canada’s most innovative cannabis extractor, is pleased to provide the following commercial and intellectual property update:

Cannabis Extraction Agreement with White Label Producer

Keep reading... Show less